Piribedil-induced sleep attacks in patients without Parkinson disease: A case series

Clinical Neuropharmacology

Volumn 34, Issue 3, 2011, Pages 104-107

  Gouraud, Aurore ^a   Millaret, Anne ^a   Descotes, Jacques ^a   Vial, Thierry ^a  

^a HOSPICES CIVILS DE LYON   (France)

Author keywords

dopamine agonists; Parkinson disease; Sleep attacks

Indexed keywords

PIRIBEDIL;

AGED; ARTICLE; CLINICAL ARTICLE; DATA BASE; DAYTIME SOMNOLENCE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PIRIBEDIL; SLEEP DISORDERS;

EID: 79959284131     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31821f0d8b     Document Type: Article

References (28)

1. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002;14:223-236.
2. Comella CL. Sleep disorders in Parkinson's disease: an overview. Mov Disord 2007;22: S367-S373. (Pubitemid 350134190)
3. De Cock VC, Vidailhet M, Arnulf I. Sleep disturbances in patients with parkinsonism. Nat Clin Pract Neurol 2008;4:254-266. (Pubitemid 351639546)
4. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910. (Pubitemid 29260911)
5. Homann CN, Homann B, Ott E, et al. Sleep attacks may not be a side effect of dopaminergic medication. Mov Disord 2003;18:1569-1570.
6. Montastruc JL, Brefel-Courbon C, Senard JM, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001;24:181-183. (Pubitemid 32549997)
7. Chaudhuri KR, Pal S, Brefel-Courbon C. "Sleep attacks" or "unintended sleep episodes" occur with dopamine agonists: is this a class effect? Drug Saf 2002;25:473-483. (Pubitemid 34827913)
8. Trivastal®20 mg, 50 mg-Summary of Product Characteristics. Servier. Last revision: 21st July 2008. Available at: http://afssaps-prd.afssaps.fr/php/ ecodex/frames.php?specid=61598530&typedoc=R&ref=R0125282.htm. Accessed December 20, 2010.
9. Tan EK. Piribedil-induced sleep attacks in Parkinson's disease. Fundam Clin Pharmacol 2003;17:117-119. (Pubitemid 36241460)
10. Bégaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985;40:111-118.
11. MedDRA MSSO Welcome. Available at: http://www.meddramsso.com/. Accessed December 20, 2010.
12. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. Br Med J 2002;324:1483-1487. (Pubitemid 34666614)
13. Monti JM, Monti D. The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 2007;11:113-133. (Pubitemid 46330853)
14. Dzirasa K, Ribeiro S, Costa R, et al. Dopaminergic control of sleep-wake states. J Neurosci 2006;26:10577-10589. (Pubitemid 44564610)
15. Lima MMS, Andersen ML, Reksidler AB, et al. Blockage of dopaminergic D2 receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation. Behav Brain Res 2008;188:406-411.
16. Ferreira JJ, Galitzky M, Montastruc JL, et al. Sleep attacks and Parkinson's disease treatment. Lancet 2000;355:1333-1334.
17. The European Agency for the evaluation of medicinal products: evaluation of medicines for human use. CPMP position statement: dopaminergic substance and sudden sleep onset. 2002 Fév 28.
18. Micallef-Roll J, Rihet P, Hasbroucq T, et al. Levodopa-induced drowsiness in healthy volunteers: results of a choice reaction time test combined with a subjective evaluation of sedation. Clin Neuropharmacol 2001;24:91-94. (Pubitemid 32294683)
19. Micallef J, Rey M, Eusebio A, et al. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexolein healthy subjects. Br J Clin Pharmacol 2009;67:333-340.
20. Andreu N, Chalé JJ, Senard JM, et al. L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol 1999;22:15-23. (Pubitemid 29161538)
21. Ferreira J, Galitzky M, Thalamas C, et al. Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology 2002;58:460-462. (Pubitemid 34150924)
22. Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005;62:1242-1248. (Pubitemid 41168351)
23. Tan EK, Lum SY, Fook-Chong SMC, et al. Evaluation of somnolence in Parkinson's disease: comparison with age-and sex-matched controls. Neurology 2002;58:465-468. (Pubitemid 34150926)
24. Ghorayeb I, Loundou A, Auquier P, et al. A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Mov Disord 2007;22:1567-1572. (Pubitemid 47477917)
25. Lagos P, Scorza C, Monti JM, et al. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats. Eur Neuropsychopharmacol 1998;8:113-120. (Pubitemid 28210337)
26. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005;9:185-200. (Pubitemid 40694186)
27. Rose AR, Antic NA, McEvoy RD. Restless leg syndrome, dopamine agonists and sleep attacks. Intern Med J 2008;38:872-873.
28. Möller JC, Körner Y, Cassel W, et al. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med 2006;7:333-339. (Pubitemid 43792897)